SynthesisWorld journal of surgical oncology2026
Gustave Roussy Immune (GRIm) score as a novel prognostic biomarker for gastrointestinal cancers: a meta-analysis of sixteen studies.
Synthesis in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Gustave Roussy immune (GRIm) score has been widely recognized as a promising prognostic biomarker in various malignancies. This study aimed to systematically evaluate the association between pretreatment GRIm score and survival outcomes in patients with gastrointestinal (GI) cancers.
methodsA systematic literature search was conducted using electronic databases (Web of Science, PubMed, Cochrane Library and Embase) from inception to January 15, 2026. The primary endpoints included long-term survival outcomes such as overall survival (OS), disease-free survival (DFS), recurrence-free survival (RFS), progression-free survival (PFS), and cancer-specific survival (CSS). Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using a random-effects model. The meta-analysis was prospectively registered with PROSPERO (CRD420261291292).
resultsThis meta-analysis included 16 studies comprising 4,904 patients with GI cancers. The pooled outcomes demonstrated that patients with a high GRIm score had significantly worse OS (15 studies; HR = 2.01; 95% CI: 1.69–2.40; P < 0.01; I² = 63%), PFS (8 studies; HR = 1.57; 95% CI: 1.29–1.91; P < 0.01; I² = 48%), DFS (2 studies; HR = 2.15; 95% CI: 1.35–3.42; P < 0.01; I² = 55%) and CSS (2 studies; HR = 1.68; 95% CI: 1.17–2.41; P < 0.01; I² = 4%) compared to those with a low score. However, a single study assessing RFS reported that the GRIm score lacked independent prognostic significance for this endpoint (HR = 1.69; 95% CI: 0.77–3.73; P = 0.19).
conclusionsOur findings suggest that the pretreatment GRIm score may serve as a prognostic biomarker in patients with GI cancers. However, further high-quality studies are required to robustly validate its prognostic utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.